Citius Oncology reports first revenue of $3.9M from LYMPHIR launch; net loss narrows to $5.5M

CITIUS ONCOLOGY, INC.

2026-Q1 EPS reported -$0.06 revenue$3,944,111

Revenue of $3.9M for Q1 FY2026 ended Dec 31, 2025, first reported sales following December 2025 commercial launch of LYMPHIR.
Net loss of $5.5M ($0.06 per share) improved from $6.7M loss ($0.09) in prior-year period.
Cash and equivalents $7.3M as of Dec 31, 2025; raised net proceeds of ~$15.1M via December 2025 registered offering.
LYMPHIR (denileukin diftitox-cxdl) launched for relapsed/refractory Stage I-III cutaneous T-cell lymphoma; patient initiations underway at leading U.S. cancer centers.
AI-enabled commercial platform deployed; international access advanced through regional distribution partners in Europe and Middle East.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.